No Data
Novartis Lifts Guidance After Profit, Sales Top Views
Novartis AG (NVS) Q1 2025 Earnings Call Transcript Summary
Novartis Q1 Earnings Beat Street View, CEO 'Confident' In Delivering Upgraded Guidance
Swiss Stocks Advance; Cosmo Shares Fall on Acne Vulgaris Drug Setback
Novartis AG (NOVN) Gets a Hold From UBS
Bernstein Sticks to Their Buy Rating for Novartis AG (NOVN)
HH1000 : aren't they doing an offering. diluting shares. it's gonna make the price drop. no thanks for buying
Tonyco HH1000 :
DazzlerAus HH1000 : they are not necessarily doing an offering S3 expire it oretty standard for these conpanies to have a standing S3 in case its needed often it just insurance against an unexpected result ie if suddenly their main drug started resulting in bad side effects